Potential Disease Modification in Dravet Syndrome: Zorevunersen Shows Promise

Groundbreaking research published in the March 5, 2026, issue of The New England Journal of Medicine details promising results for zorevunersen, an investigational RNA medicine, in treating Dravet syndrome. The data suggest the potential for disease modification in children and adolescents with this rare and devastating genetic neurodevelopmental disorder.

Understanding Dravet Syndrome

Dravet syndrome is a severe form of epilepsy that begins in infancy. It’s characterized by frequent, prolonged seizures, often triggered by fever, and developmental delays. Children with Dravet syndrome typically experience a plateau in their neurodevelopment around the age of two, falling behind their peers in achieving developmental milestones. Currently, there are no approved therapies specifically designed to modify the course of the disease.

Zorevunersen: Targeting the Root Cause

Zorevunersen is designed to address the underlying genetic cause of Dravet syndrome. The research, conducted by Stoke Therapeutics and Biogen, focused on Phase 1/2a studies and ongoing open-label extension (OLE) studies. The findings demonstrate substantial and durable reductions in seizure frequency and improvements in cognitive and behavioral measures. These positive effects were observed in individuals receiving zorevunersen in addition to their standard anti-seizure medications (ASMs).

Key Findings from the Studies

• Seizure Reduction: Participants treated with zorevunersen experienced significant and sustained reductions in the number of seizures.
• Cognitive Improvements: The studies showed improvements in multiple measures of cognition.
• Behavioral Improvements: Positive changes were also observed in behavioral assessments.
• Durable Effects: The benefits observed in the initial Phase 1/2a period continued for up to three additional years in the OLE studies.

Ongoing Research

The encouraging data from these studies are supporting an ongoing global Phase 3 EMPEROR study, further investigating the efficacy and safety of zorevunersen in a larger patient population.

Implications for Patients

The publication of these results in The New England Journal of Medicine represents a potential turning point in the treatment of Dravet syndrome. If confirmed in larger trials, zorevunersen could offer a much-needed disease-modifying therapy for individuals living with this challenging condition and their families.

The full publication, titled “Zorevunersen in Children and Adolescents with Dravet Syndrome,” appears in the March 5, 2026 issue of The New England Journal of Medicine.